KZIA - Kazia Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

131.3M

Cash

5.241M

Avg Qtr Burn

-3.789M

Short % of Float

0.08%

Insider Ownership

0.00%

Institutional Own.

1.17%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Paxalisib (GDC-0084) (PI3K pathway) Details Glioblastoma	Phase 2/3 Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cantrixil (TRX-E-002-1) Details Ovarian cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.